Practical Guidance on Mental Health and Physician Burnout

Latest News

Study: Physicians Should Prioritize Weight Management in Breast Cancer Care to Boost Survival Rates

A new study underscores the importance of weight counseling in breast cancer. Gains and losses are associated with lower chance of survival, especially in patients who undergo chemotherapy.

Learn More

Study Raises Clinical Considerations for Strategic Immunotherapy Use in Metastatic Cancer Care

New Yale study finds a significant rise in the use of immunotherapy in late-stage cancer, highlighting its growing use in end-of-life care and a greater success rate at larger institutions.

Learn More

Nearly 50% Skip Prescribed Breast Cancer Meds; Physicians Should Focus On Cost Cutting and Education

A new study suggests that cost-reduction policies and targeted interventions significantly increase adjuvant endocrine therapy adherence among breast cancer survivors.

Learn More

Criteria and Considerations for Using Newly FDA-Approved Lifileucel in Advanced Melanoma

FDA grants accelerated approval for lifileucel, a TIL therapy for advanced melanoma, marking a first for a cellular therapy targeting a solid tumor.

Learn More

Physicians Advised to Consider Rybrevant for EGFR Mutation-Positive NSCLC, Following FDA Approval

Rybrevant receives FDA approval as a game-changing treatment for NSCLC with specific genetic mutations, marking a significant advancement in personalized cancer therapy.

Learn More

Elahere Has Become A Practice-Changing Option for Platinum-Resistant, FRα Ovarian Cancer

FDA-approved Elahere for FRα-positive, platinum-resistant ovarian cancer offers new hope with its targeted mechanism and positive trial results. ​

Learn More

Integrating Venetoclax Into CLL Management Is Expanding Treatment Horizons and Improving Survival

Clinical Relevance: Venetoclax can offer your CLL patients a powerful, targeted treatment that is personalized and more effective care with fewer side effects than many other options. _________________________________________________________________________________________________________ Oncologists treating chronic lymphocytic leukemia (CLL) and select small lymphocytic lymphomas should strongly consider adding Venetoclax (Venclexta) to their arsenal, given its proven capacity to significantly enhance […]

Learn More

Balversa’s FDA Approval Means a New, Practice-Changing Option for FGFR-Positive Bladder Cancer

Clinical Relevance: Newly FDA-approved Balversa offers a targeted treatment option for patients with FGFR3-positive metastatic bladder cancer, demonstrating significant efficacy in progression-free and overall survival rates, and should be considered post platinum-containing chemotherapy or anti-PD-(L)1 therapy failures. _________________________________________________________________________________________________ Oncologists now have a new option to consider in their decision-making process thanks to the full US […]

Learn More